Risk Factors for Returning to the Operating Room for a Second Surgery After Midurethral Sling for Stress Urinary Incontinence.


Journal

Female pelvic medicine & reconstructive surgery
ISSN: 2154-4212
Titre abrégé: Female Pelvic Med Reconstr Surg
Pays: United States
ID NLM: 101528690

Informations de publication

Date de publication:
07 2020
Historique:
pubmed: 29 3 2020
medline: 25 8 2021
entrez: 29 3 2020
Statut: ppublish

Résumé

The objective of this study was to identify risk factors for having to return to the operating room for a second surgery after midurethral sling (MUS). We used a case-control design. Cases return to operating room were a composite of 6 surgical complications or recurrent stress urinary incontinence because we believed that women would consider return to the operating room (OR) a similar MUS-related complication regardless of indication. Cases were obtained from Cerner Health Facts database, including 213 hospitals, using current procedural technology codes 57288 (repeat sling), 57287 (sling revision), and 53500 (urethrolysis) for procedures after index MUS. Controls no return to OR were randomly selected in 4:1 ratio from the remaining slings without these procedures. Multivariable regression analysis included all variables with P < 0.10 on univariable analysis. Between January 1, 2010, and December 31, 2016, 1247 patients returned to the OR of 17,953 patients who underwent initial MUS (6.9%). After adjusting for confounders, white race (OR, 1.47 [1.20-1.81]), lack of concomitant prolapse surgery (OR, 1.37 [1.18-1.59]), immunosuppressant drugs (OR, 1.27 [1.12-1.45]), and blood thinner use (OR, 1.38 [1.18-1.62]) significantly impacted the odds for returning to the OR. Anticholinergic use and smoking tobacco or marijuana, although significant on univariable analysis, were no longer significant after adjusting for confounders. The rate of a second surgery after MUS using a composite outcome, over a 7-year period including multiple diagnoses, is 6.9%. White race, using immunosuppressant drugs, using blood thinners, and not having concomitant prolapse surgery are all risk factors for having second surgery after MUS.

Identifiants

pubmed: 32217917
doi: 10.1097/SPV.0000000000000804
pii: 01436319-202007000-00006
pmc: PMC9753142
mid: NIHMS1854256
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

443-446

Subventions

Organisme : NIBIB NIH HHS
ID : R21 EB025272
Pays : United States

Références

Obstet Gynecol. 2014 Jun;123(6):1207-1212
pubmed: 24807335
Int Urogynecol J. 2016 Jan;27(1):117-22
pubmed: 26134541
Biomed Res Int. 2016;2016:1242061
pubmed: 27999787
J Urol. 2010 Jan;183(1):241-6
pubmed: 19913831
Am J Obstet Gynecol. 2013 Jan;208(1):73.e1-7
pubmed: 23099189
Obstet Gynecol. 2017 Jun;129(6):1124-1130
pubmed: 28486368
Int Urogynecol J. 2013 May;24(5):775-80
pubmed: 22930217
Obstet Gynecol. 2012 Mar;119(3):539-46
pubmed: 22353951
Urology. 2016 Sep;95:72-9
pubmed: 27196030
J Biol Chem. 2007 Feb 9;282(6):4021-34
pubmed: 17095510
Cochrane Database Syst Rev. 2017 Jul 31;7:CD006375
pubmed: 28756647
Int J Urol. 2014 Nov;21(11):1167-70
pubmed: 25039945
Obstet Gynecol. 2013 Feb;121(2 Pt 1):273-278
pubmed: 23344276
Female Pelvic Med Reconstr Surg. 2014 May-Jun;20(3):123-5
pubmed: 24763151
Arch Med Sci. 2015 Oct 12;11(5):982-8
pubmed: 26528340
Int Urogynecol J. 2010 Feb;21(2):149-55
pubmed: 19855914
Int Urogynecol J. 2010 Oct;21(10):1253-9
pubmed: 20552167
Int Urogynecol J. 2012 Jul;23(7):831-41
pubmed: 22576328
Am J Obstet Gynecol. 2016 Aug;215(2):206.e1-8
pubmed: 27094962
Female Pelvic Med Reconstr Surg. 2016 May-Jun;22(3):140-5
pubmed: 26825409
Nat Rev Urol. 2015 Sep;12(9):481-509
pubmed: 26282209
Am J Obstet Gynecol. 2009 Aug;201(2):202.e1-8
pubmed: 19560115
Am J Obstet Gynecol. 2008 Nov;199(5):546.e1-8
pubmed: 18639207
Obstet Gynecol. 2011 Apr;117(4):913-921
pubmed: 21422865
J Urol. 2011 Aug;186(2):589-93
pubmed: 21684555
Int Urogynecol J. 2013 Apr;24(4):645-53
pubmed: 22875405
Int Urogynecol J. 2016 Sep;27(9):1321-6
pubmed: 26811112
J Postgrad Med. 1997 Apr-Jun;43(2):52-6
pubmed: 10740722

Auteurs

Fatima Sharif (F)

From the Department of Obstetrics and Gynecology, School of Medicine, University of Missouri Kansas City, Kansas City, MO.

Fizza Mahmud (F)

From the Department of Obstetrics and Gynecology, School of Medicine, University of Missouri Kansas City, Kansas City, MO.

Sahil Suman (S)

From the Department of Obstetrics and Gynecology, School of Medicine, University of Missouri Kansas City, Kansas City, MO.

An-Lin Cheng (AL)

From the Department of Obstetrics and Gynecology, School of Medicine, University of Missouri Kansas City, Kansas City, MO.

Jonathan P Shepherd (JP)

Trinity Health of New England, Hartford, CT.

Gary Sutkin (G)

From the Department of Obstetrics and Gynecology, School of Medicine, University of Missouri Kansas City, Kansas City, MO.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH